Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Knight Therapeutics Inc.TSX: GUD.TO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of CA$13.17M rose 502.7% year over year, ahead of the -49.3% change in trailing-twelve-month net income. Sequentially, it rose 48.7% from the prior quarter. Over 3 fiscal years it compounded at -43.6% a year.

Context

  • Net income amounted to 1.2% of revenue in FY2025, unchanged from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of CA$13.55M (+352.2%) for the fiscal year ending Dec 2026, a step up from the -224.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$13.17M+48.7% QoQ
Last fiscal yearDec 2025
-CA$5.37M-224.1% YoY
LTMMar 2026
CA$5.61M-49.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+502.7%+109.2%-393.5 pp
1 year-224.1%+352.2%+576.3 pp
3-year CAGR-43.6%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CAD · from the cash flow

Latest · FY2025
(5.37M) CAD
Year-over-year change
-224.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -49.3% is the 4th highest of 8, against a peer median of -56.4%.
  • Net income amounts to 1.1% of revenue for GUD.TO, versus a peer median of 12.7%.
GUD.TO Competitors
Net Income for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$263.55M CAD-56.4%-28.6%84.8%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$50.24M CAD-418.7%-39.5%15.8%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$31.07M USD+236.1%+0.9%61.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$25.21M CAD-249.3%—9.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$20.19M USD-71.2%—7.7%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$8.44M CAD+276.1%-36.4%12.7%
VHI.TOVitalhub Corp.LTM Mar 2026CA$7.3M CAD+157.0%+71.4%6.1%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$5.61M CAD-49.3%-43.6%1.1%
Peer median (excluding GUD.TO) —-56.4%-28.6%12.7%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
Deferred Income Tax(7.64M)(17.13M)(9.13M)(3.24M)(3.81M)
Stock-Based Compensation3.05M1.89M2.33M1.86M8.11M
Change in Working Capital627K(9.99M)(28.01M)(19.62M)1.89M
Accounts Receivables8.59M(26.42M)5.58M(10.29M)(26.53M)
Inventory(17.19M)(11.43M)698K(5.91M)(17.82M)
Accounts Payables11.46M30.6M(21.63M)632K42.11M
Other Working Capital(2.23M)(2.74M)(12.66M)(4.06M)4.14M
Other Non-Cash Items(15.01M)32.98M37.19M(154K)12.91M
Operating Cash Flow44.62M40.48M35.94M36.28M70.3M
Capital Expenditures(224.18M)(25.82M)(9.96M)(31.47M)(1.91M)
Acquisitions (Net)(220.35M)000(110.05M)
Purchases of Investments(64.32M)(185.47M)(334.16M)(162.57M)(70.39M)
Sales of Investments180.54M150.54M345.47M196.12M112.43M
Other Investing Activities223.04M(2.33M)18.99M(14.12M)17.6M
Investing Cash Flow(105.28M)(63.08M)29.34M16.96M(84.11M)
Debt Repayment(14.19M)31.49M(18.02M)(18.05M)23.19M
Common Stock Issued0000511K
Common Stock Repurchased(64.42M)(30.07M)(53.48M)(8.87M)(6.35M)
Dividends Paid00000
Other Financing Activities297K(4.18M)(9.5M)(6.62M)(4.34M)
Financing Cash Flow(78.31M)1.76M(81M)(33.54M)13.01M
Effect of Forex Changes(4.66M)6.55M2.8M1.64M(2.86M)
Net Change in Cash(143.63M)(14.28M)(12.92M)21.35M(3.66M)
Free Cash Flow(179.57M)14.67M25.98M4.81M68.4M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.